Mast Therapeutics, Inc.

Quick facts

Marketed products

• poloxamer 188

Phase 3 pipeline

• CoFactor (ANX-510) · Rare Genetic/Metabolic Disorders
  CoFactor (ANX-510) is a cofactor replacement therapy designed to restore deficient cofactor levels in patients with certain metabolic or genetic disorders.

Phase 2 pipeline

• CoFactor
• CoFactor and 5FU

Phase 1 pipeline

• ANX-188 Supratherapeutic dose
• ANX-188 Therapeutic Dose
• ANX-514

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mast Therapeutics, Inc. portfolio CI brief
• Mast Therapeutics, Inc. pipeline updates RSS